Skip to main content
ComparisonUpdated Oct 2026

PT-141 vs Melanotan II: Sexual-Function Evidence and Differences

PT-141 and Melanotan II share melanocortin biology, but the useful comparison is more specific than sexual effects versus tanning. Product identity, the population studied and the outcome measured determine what the evidence can support. Research findings and personal reports should not be treated as interchangeable treatment instructions.

By the Peptide Dossier Editorial TeamUpdated How we source

PT-141 vs Melanotan II at a Glance

Pt 141 vs melanotan 2 comparison table
FactorPT-141Melanotan II
Primary PurposeHSDD trials and earlier male erectile-response researchEarly pigmentation and male erectile-response research
Onset TimeProduct timing is not a guaranteed response timeAcute responses measured within six-hour study visits
Peak EffectNo universal clinical peak established hereNo universal clinical peak established here
Tanning EffectFocal hyperpigmentation can occurPigmentation observed in a small pilot
Appetite EffectNot established here as a weight-management treatmentA reported appetite effect does not establish weight-loss efficacy
Dosage PatternApproved-product instructions are described belowExperimental schedules are not general treatment instructions
Duration per DoseClinical efficacy duration is unknownObservation windows do not establish a universal duration
Cost per UseRequires a current product-and-service quoteVial prices alone do not establish clinical value

An approved medicine, an experimental preparation and an online product listing are different things. The table should help identify those differences, not turn results from separate studies into a direct competition. Study context and original sources follow below.

Mechanisms: Shared Receptors, Different Evidence

Bremelanotide activates several melanocortin receptors, including MC1R and MC4R; its clinical HSDD mechanism remains unknown. MC1R activity can affect pigmentation. Current Vyleesi prescribing information

The early Melanotan II pilot involved three men and found increased pigmentation in two, alongside intermittent erections after dosing. The study supports biological activity, but its size cannot establish a reliable benefit or safety profile for routine use. Tanning and sexual outcomes should be evaluated separately. 1996 Melanotan II pilot study

Sexual Function: Different Populations and Outcomes

Two 24-week RECONNECT trials randomized 1,267 premenopausal women with hypoactive sexual desire disorder to bremelanotide or placebo. Bremelanotide improved the prespecified desire and related-distress scores. The number of satisfying sexual events did not differ significantly, while a favorable analysis of the proportion of encounters rated satisfying was post hoc. These are distinct results, not a guarantee of sexual performance. 2019 RECONNECT randomized trials

Early male PT-141 research is also relevant. A 2004 intranasal study reported greater instrument-measured erectile responses than placebo in healthy men and sildenafil-responsive ED patients; first erections occurred at approximately 30 minutes. Flushing and nausea were common adverse events, although investigators reported favorable short-term tolerability. These nasal-preparation findings are not instructions for substituting a spray for an approved injection. 2004 intranasal PT-141 male studies

A separate subcutaneous study found increased erectile responses in healthy men and in ED patients reporting inadequate sildenafil response. The patient crossover tested 4 and 6 mg with visual sexual stimulation; both doses differed significantly from placebo, with favorable tolerability reported. These are research exposures, not a recommended male regimen or evidence that escalating an individual dose is beneficial. 2004 subcutaneous PT-141 male studies

Melanotan II also has small human studies worth discussing. In a ten-man placebo-controlled crossover study of erectile dysfunction without a known organic cause, erections occurred in eight men after Melanotan II. Rigidity was measured during a six-hour observation period. This is acute experimental evidence, not support for a universal three-to-seven-day delay before sexual effects. 1998 Melanotan II crossover study

A separate ten-man crossover study involving organic erectile-dysfunction risk factors reported erections after 12 of 19 Melanotan II injections versus one of 21 placebo injections. Sexual desire also increased. The injection counts are not patient response percentages, and neither small study establishes a routine maintenance schedule or a head-to-head advantage over bremelanotide. 2000 Melanotan II organic-ED study

Safety: Keep the Favorable Findings and Their Limits

In RECONNECT, nausea occurred in 40.0% of bremelanotide recipients versus 1.3% with placebo; most episodes were transient and mild or moderate, but 8.1% discontinued treatment because of nausea. Flushing and headache were also more frequent. Calling nausea rare would misrepresent the trial. 2019 RECONNECT randomized trials

Vyleesi is contraindicated with uncontrolled hypertension or known cardiovascular disease. It can raise blood pressure, reduce heart rate and cause persistent focal hyperpigmentation. Oral-drug absorption may change; avoid combining it with oral naltrexone for addiction. Use contraception and discontinue Vyleesi if pregnancy is suspected. Current Vyleesi prescribing information

A 52-week open-label extension reported sustained symptom improvements and no new safety signals. However, 684 women enrolled and 272 completed it; participants had already completed the controlled phase without serious adverse events. The additional follow-up is useful, but selection, attrition and the absence of a concurrent placebo group limit comparisons. 2019 open-label bremelanotide extension

Melanotan II's small organic-ED trial recorded severe nausea after four of 19 injections. A separate case report documented systemic toxicity, muscle breakdown and kidney dysfunction after a chemically confirmed internet-sourced product. A case report cannot estimate how often an event occurs, but it contradicts the claim that serious events have not been documented. 2000 Melanotan II organic-ED study 2012 chemically confirmed Melanotan II toxicity report

Uses: Match the Product to the Clinical Question

Vyleesi is approved for acquired, generalized HSDD in premenopausal women, excluding medical, psychiatric, relationship or drug causes. It is not indicated for men, postmenopausal women or performance enhancement. Current Vyleesi prescribing information

That defined indication does not erase research in other populations, but research and approval answer different questions. Melanotan II's small male trials are relevant to erectile response; they do not establish female sexual-function treatment, weight-loss therapy or a broadly beneficial year-round regimen.

Personal accounts can help describe experiences and generate research questions. A useful report identifies the preparation, concurrent medication, diagnosis and timing. A perceived improvement without those details cannot establish that one peptide is the best choice for everyone.

Dosing and Preparation: Product Instructions Are Specific

Vyleesi's labeled dose is 1.75 mg subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity: no repeat within 24 hours, and over eight monthly doses is not recommended. Stop after eight weeks without improvement. Its prefilled autoinjector needs no reconstitution; store at or below 25°C, protected from light, without freezing. Current Vyleesi prescribing information

Those instructions describe the approved product, not a conversion chart for an unidentified research vial or nasal spray. Preparation-specific pharmacy directions cannot be replaced by assuming that every product with the same ingredient name has the same concentration, storage requirements or delivery characteristics.

The sources reviewed here do not validate a universal Melanotan II loading-and-maintenance schedule or a repeated same-day combination protocol. Trial exposures belong with their monitored study context, rather than becoming instructions for increasing a dose until an effect appears.

Cost: Compare Equivalent Products and Care

A useful price comparison needs a current quote for a named preparation and service. Include the quantity supplied, dispensing and consultation charges, supplies, follow-up and any separate testing costs. A research-vial listing and a prescribed treatment program are not equivalent purchases.

Cost per use cannot be established without a specified dose and usable supply. A low vial price does not demonstrate clinical value, and combining unverified price assumptions with an unsupported maintenance schedule does not create a reliable monthly budget.

Combination Use: A Hypothesis Is Not a Proven Protocol

Shared melanocortin activity is a reason to investigate combined exposure, not proof of complementary benefit. The sources reviewed here do not compare PT-141 plus Melanotan II against either alone for sexual function, tanning or adverse effects.

Practitioner experience can be discussed when the preparation and clinical circumstances are clear. It does not establish additive efficacy, dose compatibility or a safe injection calendar. Familiarity with each substance separately does not establish the effects of using them together.

Which Evidence Fits the Question?

For low desire with distress, begin with a clinical assessment of the cause rather than choosing a peptide by reputation. For erectile difficulty, the relevant endpoint is different. Tanning is another separate aim. Combining these questions into a single best-peptide ranking obscures the evidence.

The larger bremelanotide program and the small Melanotan II experiments answer different questions in different populations. The latter retain value as early human research, but a direct winner cannot be calculated from unmatched studies.

Verdict: More Useful Than a Universal Winner

Both research histories contain meaningful biological and clinical observations. The useful distinction is the strength and relevance of the evidence for a specific person and outcome, not a promise that one compound delivers every desired effect without trade-offs.

Use the linked studies to separate measured outcomes from personal experience. A treatment discussion should identify the actual product, diagnosis, expected benefit, medication interactions and follow-up, without converting an experimental observation into an unsourced dosing plan.

Frequently Asked Questions

Vyleesi is taken at least 45 minutes before sexual activity; that is not a guaranteed onset. Small Melanotan II studies recorded acute erectile responses during six-hour visits, not a universal multiday loading period. These findings concern different populations and endpoints.

Melanotan II increased pigmentation in an early pilot. Bremelanotide can cause focal hyperpigmentation. Neither finding establishes a predictable cosmetic result or justifies increasing exposure to achieve one.

The bremelanotide extension adds one year of open-label follow-up, with substantial attrition. It is not a direct comparison with Melanotan II. The reviewed evidence cannot establish a universal long-term safety winner; adverse events and individual clinical circumstances still matter.

The sources reviewed here do not establish the combination's added benefit, safety or dosing compatibility. Shared receptor activity does not prove that combining them improves outcomes. Discuss the actual preparations and other medications rather than relying on a sample stack.

Bremelanotide improved desire and related distress in premenopausal women with HSDD in RECONNECT. That does not establish a general sexual-performance benefit for every woman. The small Melanotan II male studies cannot answer the female-treatment question.

Vyleesi's per-dose efficacy duration is unknown. The Melanotan II studies do not establish a general schedule for effects to fade after stopping. Sexual response, pigmentation and drug clearance are different measures and should not be assigned one shared timeline.

Medical Disclaimer

This comparison explains research and product differences, not an individualized treatment or injection plan.

Related Comparisons & Resources

Rankings reflect editorial judgment.